Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
Clinical trial NCT03923270 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03923270
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-06
- Primary completion
- 2023-06-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.